Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ECYT's Cash to Debt is ranked higher than
78% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. ECYT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ECYT' s 10-Year Cash to Debt Range
Min: 0.69  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.97
ECYT's Equity to Asset is ranked higher than
97% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ECYT: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
ECYT' s 10-Year Equity to Asset Range
Min: 0.45  Med: 0.54 Max: 0.97
Current: 0.97
0.45
0.97
Interest Coverage 5027.00
ECYT's Interest Coverage is ranked lower than
80% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ECYT: 5027.00 )
Ranked among companies with meaningful Interest Coverage only.
ECYT' s 10-Year Interest Coverage Range
Min: 5027  Med: 5027.00 Max: 5027
Current: 5027
F-Score: 4
Z-Score: 20.24
M-Score: -1.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5.12
ECYT's Operating margin (%) is ranked higher than
66% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. ECYT: -5.12 )
Ranked among companies with meaningful Operating margin (%) only.
ECYT' s 10-Year Operating margin (%) Range
Min: -20228.8  Med: -285.43 Max: 7.15
Current: -5.12
-20228.8
7.15
Net-margin (%) -4.27
ECYT's Net-margin (%) is ranked higher than
65% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. ECYT: -4.27 )
Ranked among companies with meaningful Net-margin (%) only.
ECYT' s 10-Year Net-margin (%) Range
Min: -21220.94  Med: -308.37 Max: 7.76
Current: -4.27
-21220.94
7.76
ROE (%) -1.24
ECYT's ROE (%) is ranked higher than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. ECYT: -1.24 )
Ranked among companies with meaningful ROE (%) only.
ECYT' s 10-Year ROE (%) Range
Min: -492.46  Med: -17.72 Max: 3.72
Current: -1.24
-492.46
3.72
ROA (%) -1.12
ECYT's ROA (%) is ranked higher than
73% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. ECYT: -1.12 )
Ranked among companies with meaningful ROA (%) only.
ECYT' s 10-Year ROA (%) Range
Min: -86.45  Med: -31.51 Max: 2.91
Current: -1.12
-86.45
2.91
ROC (Joel Greenblatt) (%) -59.30
ECYT's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. ECYT: -59.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ECYT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3911.11  Med: -1455.18 Max: 139.85
Current: -59.3
-3911.11
139.85
Revenue Growth (3Y)(%) 451.80
ECYT's Revenue Growth (3Y)(%) is ranked higher than
99% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ECYT: 451.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ECYT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -16.70 Max: 451.8
Current: 451.8
0
451.8
» ECYT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ECYT Guru Trades in Q2 2014

Jim Simons 210,200 sh (New)
RS Investment Management Sold Out
Paul Tudor Jones 37,400 sh (-25.20%)
» More
Q3 2014

ECYT Guru Trades in Q3 2014

Joel Greenblatt 17,450 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 111,700 sh (-46.86%)
» More
Q4 2014

ECYT Guru Trades in Q4 2014

Jim Simons 537,405 sh (+381.11%)
Joel Greenblatt Sold Out
» More
Q1 2015

ECYT Guru Trades in Q1 2015

Jim Simons 379,100 sh (-29.46%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.14
ECYT's P/B is ranked higher than
93% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. ECYT: 1.14 )
Ranked among companies with meaningful P/B only.
ECYT' s 10-Year P/B Range
Min: 0.97  Med: 2.88 Max: 11.64
Current: 1.14
0.97
11.64
P/S 4.31
ECYT's P/S is ranked higher than
76% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. ECYT: 4.31 )
Ranked among companies with meaningful P/S only.
ECYT' s 10-Year P/S Range
Min: 2.43  Med: 8.29 Max: 1100
Current: 4.31
2.43
1100
Current Ratio 29.35
ECYT's Current Ratio is ranked higher than
94% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. ECYT: 29.35 )
Ranked among companies with meaningful Current Ratio only.
ECYT' s 10-Year Current Ratio Range
Min: 1.26  Med: 4.14 Max: 29.35
Current: 29.35
1.26
29.35
Quick Ratio 29.35
ECYT's Quick Ratio is ranked higher than
94% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ECYT: 29.35 )
Ranked among companies with meaningful Quick Ratio only.
ECYT' s 10-Year Quick Ratio Range
Min: 1.26  Med: 4.14 Max: 29.35
Current: 29.35
1.26
29.35
Days Sales Outstanding 0.82
ECYT's Days Sales Outstanding is ranked higher than
99% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. ECYT: 0.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ECYT' s 10-Year Days Sales Outstanding Range
Min: 3.66  Med: 35.75 Max: 59.87
Current: 0.82
3.66
59.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.45
ECYT's Price/Net Cash is ranked higher than
97% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. ECYT: 1.45 )
Ranked among companies with meaningful Price/Net Cash only.
ECYT' s 10-Year Price/Net Cash Range
Min: 1.22  Med: 3.50 Max: 32.02
Current: 1.45
1.22
32.02
Price/Net Current Asset Value 1.43
ECYT's Price/Net Current Asset Value is ranked higher than
96% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. ECYT: 1.43 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ECYT' s 10-Year Price/Net Current Asset Value Range
Min: 1.21  Med: 3.33 Max: 17.28
Current: 1.43
1.21
17.28
Price/Tangible Book 1.13
ECYT's Price/Tangible Book is ranked higher than
94% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. ECYT: 1.13 )
Ranked among companies with meaningful Price/Tangible Book only.
ECYT' s 10-Year Price/Tangible Book Range
Min: 1.19  Med: 3.24 Max: 9.84
Current: 1.13
1.19
9.84
Price/Projected FCF 10.41
ECYT's Price/Projected FCF is ranked lower than
72% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. ECYT: 10.41 )
Ranked among companies with meaningful Price/Projected FCF only.
ECYT' s 10-Year Price/Projected FCF Range
Min: 12.27  Med: 14.20 Max: 16.13
Current: 10.41
12.27
16.13
Price/Median PS Value 0.52
ECYT's Price/Median PS Value is ranked higher than
86% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. ECYT: 0.52 )
Ranked among companies with meaningful Price/Median PS Value only.
ECYT' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 1.04 Max: 62.25
Current: 0.52
0.31
62.25
Earnings Yield (Greenblatt) (%) -3.80
ECYT's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. ECYT: -3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ECYT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -3.8  Med: 7.30 Max: 684.3
Current: -3.8
-3.8
684.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9EY.Germany,
Endocyte Inc was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. The Company completed its initial public offering on April 2, 2014. The Company is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The Company's SMDC Pipeline products include Vintafolide designed to deliver a cytotoxic drug payload directly to folate receptors that are over-expressed on cancer cells, with low toxicity to healthy cells; EC1456 is a second generation folate receptor-targeted SMDC. It is a conjugate of folate and an anti-cancer drug payload of tubulysin, a microtubule destabilizer; EC1169 is non-folate targeted SMDC and is designed to specifically target PSMA; EC1788 is a folate receptor-targeted SMDC in preclinical development with a very potent DNA alkylator drug; EC1669 is a folate receptor-targeted SMDC in preclinical development for treatment in inflammatory diseases; and EC0371 is a folate receptor-targeted SMDC in preclinical development for treatment of polycystic kidney disease. The Company faces competition from other pharmaceutical companies, biotechnology companies, public and private universities and research organizations. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
comment on ECYT Mar 06 2013 
Merck: Ready to Rise on New Drugs Apr 18 2012 
3.13 Jan 30 2012 
Lots of insider trad Jan 13 2012 

More From Other Websites
Endocyte to Present at the Cantor Fitzgerald Healthcare Conference Jul 01 2015
Endocyte to Present at the Cantor Fitzgerald Healthcare Conference Jul 01 2015
ENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... May 18 2015
ENDOCYTE INC Financials May 15 2015
Endocyte Announces Updated Data on EC1456 and EC1169 at the 2015 American Society of Clinical... May 13 2015
Endocyte Announces Updated Data on EC1456 and EC1169 at the 2015 American Society of Clinical... May 13 2015
ENDOCYTE INC Files SEC form 10-Q, Quarterly Report May 08 2015
Endocyte reports 1Q loss May 07 2015
Endocyte reports 1Q loss May 07 2015
ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
Endocyte Reports First Quarter 2015 Financial Results and Provides Update on Clinical Progress May 07 2015
Q1 2015 Endocyte Inc Earnings Release - Time Not Supplied May 07 2015
Endocyte Announces First Quarter 2015 Earnings Conference Call Apr 30 2015
Endocyte Announces First Quarter 2015 Earnings Conference Call Apr 30 2015
Will Endocyte (ECYT) Disappoint This Earnings Season? - Analyst Blog Apr 29 2015
Express Scripts Posts In-line Q1 Earnings, Revenues Beat - Analyst Blog Apr 29 2015
Endocyte Announces Presentations at American Association for Cancer Research (AACR) 2015 Annual... Apr 10 2015
Endocyte Announces Presentations at American Association for Cancer Research (AACR) 2015 Annual... Apr 10 2015
Endocyte Appoints P. David Mozley, M.D. as Vice President of Imaging Apr 07 2015
Endocyte Appoints P. David Mozley, M.D. as Vice President of Imaging Apr 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK